Victor Forge
Metformin is a widely prescribed anti-diabetic drug that has been used for over half a century. It is known to cause muscle atrophy, a severe condition that involves loss of muscle mass and quality. However, recent studies have found that metformin can also reduce muscle atrophy and improve muscle recovery in the elderly, making it a potential therapeutic solution for muscle disuse and recovery from injuries. The effect of metformin on muscle atrophy is still controversial, with some studies suggesting that it impairs muscle function through the regulation of myostatin in skeletal muscle cells, while others show that it enhances skeletal muscle function and regeneration.
Explore related products
What You'll Learn
- Metformin's impact on muscle atrophy in humans with type 2 diabetes is unknown
- Metformin's role in muscle wasting regulation at the transcriptional level
- Metformin's effect on muscle recovery and disuse atrophy in the elderly
- Metformin's impact on muscle mass and function in rats of different ages
- Metformin's ability to mitigate muscle atrophy post-burn injury
Metformin's impact on muscle atrophy in humans with type 2 diabetes is unknown
Metformin is a widely prescribed anti-diabetic drug for patients with type 2 diabetes. Skeletal muscle atrophy is a severe condition that involves the loss of muscle mass and quality. Drug intake is one of the causes of muscle atrophy.
Several studies have found that metformin can induce muscle atrophy by regulating myostatin in skeletal muscle cells via the AMPK-FoxO3a-HDAC6 axis. Myostatin is a molecule that regulates muscle volume and triggers the phosphorylation of AMPK. The muscle-wasting effect of metformin is more evident in WT than in db/db mice, indicating that more complicated mechanisms may be involved in metformin-mediated muscle dysfunction.
However, the impact of metformin on muscle atrophy in humans with type 2 diabetes is unknown. The molecular mechanism of metformin in muscle is unclear, and more research is needed to understand its effects. Some studies have shown that metformin can enhance skeletal muscle function and protect against muscle atrophy, especially during recovery periods after injury or illness. For example, a study by Petrocelli and Drummond (2020) found that metformin can delay skeletal muscle aging, atrophy, and functional recovery by activating PGC-1α, which inhibits muscle atrophy.
Additionally, metformin has been found to have anti-senescent properties, which can help with muscle recovery and maintaining muscle mass and function as individuals age. A study by Ai et al. (2021) suggested that metformin use was a protective factor for the development of sarcopenia in patients with type 2 diabetes. However, another study by Walton et al. (2019) found that metformin blunted muscle hypertrophy in response to progressive resistance exercise training in older adults.
In conclusion, while metformin has been shown to induce muscle atrophy in some studies, its impact on muscle atrophy in humans with type 2 diabetes is still unclear and requires further investigation. More research is needed to understand the complex mechanisms involved in metformin-mediated muscle dysfunction and its potential benefits in maintaining muscle mass and function.
Muscle Loss and Autoimmune Diseases: Uncovering the Mystery
You may want to see also
Explore related products
Metformin's role in muscle wasting regulation at the transcriptional level
Skeletal muscle atrophy is a severe condition that involves the loss of muscle mass and quality. It is caused by a combination of factors, including mitochondrial changes, chronic inflammation, insulin resistance, and impaired muscle regeneration. Metformin, a widely prescribed anti-diabetic drug, has been found to induce muscle atrophy through transcriptional regulation. However, its exact molecular mechanism is still unclear and remains a subject of ongoing research.
Metformin is known to increase the levels of p-AMPK and myostatin, a muscle atrophy-related molecule. Myostatin expression was investigated at the protein and transcript levels after metformin administration, revealing that metformin induced the expression of myostatin, which regulates muscle volume and triggers AMPK phosphorylation. In vitro results indicate that the up-regulation of myostatin in response to metformin is controlled by activated p-AMPK, which enables binding between FoxO3a and myostatin. FoxO3a binds to the putative binding site of myostatin in the promoter region, directly activating its expression.
The muscle-wasting effects of metformin are more evident in wild-type (WT) mice than in db/db mice, suggesting that more complex mechanisms may be involved in metformin-mediated muscular dysfunction. Additionally, metformin treatment impairs muscle function through the regulation of myostatin in skeletal muscle cells via the AMPK-FoxO3a-HDAC6 axis. HDAC6 may also play a role in regulating muscle atrophy by mediating myostatin up-regulation through its deacetylation activity.
While metformin has been shown to induce muscle atrophy, some studies suggest that it can also enhance skeletal muscle function. For example, metformin has been found to promote the expression of PGC-1α, which can downregulate FoxO3 to prevent muscle atrophy and protect muscle function. Furthermore, when combined with exercise therapy, metformin has been shown to inhibit muscle mass loss and improve muscle function. However, the effects of metformin on muscle appear to be influenced by age and metabolic factors, and long-term administration can lead to decreased androgen and estrogen levels.
Muscle Stiffness: Autoimmune Diseases and Their Causes
You may want to see also
Explore related products
Metformin's effect on muscle recovery and disuse atrophy in the elderly
Metformin is the most widely prescribed anti-diabetic drug for patients with type 2 diabetes. It is a biguanide that regulates blood sugar and improves insulin sensitivity. However, its long-term administration can cause several side effects, including those that affect muscle function. Metformin has been found to induce muscle atrophy by impairing muscle function through the regulation of myostatin in skeletal muscle cells via the AMPK-FoxO3a-HDAC6 axis.
The muscle-wasting effect of metformin is more evident in WT than in db/db mice, indicating that more complicated mechanisms may be involved in metformin-mediated muscular dysfunction. Metformin up-regulates myostatin expression, a key molecule that regulates muscle volume and triggers the phosphorylation of AMPK, leading to muscle atrophy. However, the effect of metformin on muscle is still controversial, and blood glucose levels and other conditions can also induce muscle atrophy.
Recent studies have shown that metformin can reduce muscle atrophy and improve muscle recovery in the elderly. University of Utah Health researchers have found that metformin can target senescent cells, which accumulate with age and impact muscle function by secreting factors associated with inflammation and fibrotic tissue formation. In a study involving healthy older adults and a period of bed rest, participants who took metformin had less muscle atrophy and fibrosis during the recovery period. Metformin helped muscle cells remodel and repair tissue, maintaining muscle mass and function as individuals age.
Additionally, metformin has been found to alleviate muscle wasting post-thermal injury by increasing Pax7-positive muscle progenitor cells. It enhances muscle regeneration and stem cell function, increasing protein synthesis in skeletal muscle and mitigating muscle atrophy. The combination of metformin with exercise therapy has been shown to inhibit muscle mass loss and loss of function, making it a potential therapeutic solution for disuse atrophy and muscle recovery in the elderly.
While the exact molecular mechanism of metformin's effect on muscle is not yet fully understood, its ability to reduce muscle atrophy and improve recovery in the elderly is a promising area of research, with potential applications in maintaining muscle health and functionality during aging.
Pulled Muscles: Can They Cause Fever?
You may want to see also
Explore related products
Metformin's impact on muscle mass and function in rats of different ages
Metformin is a drug that has been used in clinical practice for over 60 years, primarily as an anti-diabetic treatment. It is also believed to have therapeutic and preventative applications in ageing-related diseases such as cancer, cardiovascular disease, and degenerative osteoarthrosis.
There is some evidence that metformin can cause muscle atrophy. This is believed to be due to the transcriptional regulation of myostatin via HDAC6 and FoxO3a, which impairs muscle function. However, the effect of metformin on muscle is still controversial and is believed to be influenced by age and metabolic factors.
In rats, the impact of metformin on muscle mass and function appears to be influenced by the age of the rat. Researchers defined 12-month-old rats as "adults" and 18-month-old rats as "old". Adult rats administered metformin showed a decrease in whole-body lean tissue mass with no significant change in body fat content compared to controls. However, older rats (from 18 to 24 months) administered metformin showed an increase in muscle and bone.
In a study by Hernández-Álvarez et al. (2019), it was found that metformin combined with exercise therapy can inhibit muscle mass loss and loss of function in older rats. Similarly, Morales-Salazar et al. (2019) found that long-term moderate exercise combined with metformin treatment prevented strength and muscle mass loss in old female Wistar rats.
Another study by Fitzgerald et al. (2016) used a rat model with different intrinsic aerobic capacities (high-capacity runner/low-capacity runner [HCR/LCR]) to understand the context specificity of metformin treatment on skeletal muscle. They found that metformin caused lower ADP-stimulated respiration in LCRs, with less of a change in HCRs. A washout of metformin resulted in an unexpected doubling of respiratory capacity in HCRs, accompanied by mitochondrial remodelling that included increases in protein synthesis and morphological changes. These results suggest that the impact of metformin on skeletal muscle is dependent on baseline intrinsic mitochondrial function.
In summary, while metformin has been shown to cause muscle atrophy in some studies, its effect on muscle mass and function in rats appears to be influenced by age and other metabolic factors. Further research is needed to fully understand the impact of metformin on muscle and to resolve the inconsistencies in the current findings.
Understanding Heart Muscle Spasms: Causes and Triggers
You may want to see also
Explore related products
Metformin's ability to mitigate muscle atrophy post-burn injury
Skeletal muscle atrophy, a severe condition involving the loss of muscle mass and quality, can be caused by drug intake. Metformin, the most widely prescribed anti-diabetic drug for patients with type 2 diabetes, has been found to induce muscle atrophy through the transcriptional regulation of myostatin, a molecule that regulates muscle volume. However, metformin's ability to mitigate muscle atrophy post-burn injury has also been observed.
Profound skeletal muscle wasting and weakness are common after severe burns, persisting for years and contributing to the morbidity and mortality of burn patients. While no ideal treatment exists to inhibit muscle catabolism, metformin has been found to alleviate muscle wasting post-thermal injury. Metformin is an anti-diabetic agent that manages hyperglycemia and has a beneficial effect on stem cells after injury. Studies have shown that metformin treatment increases gastrocnemius muscle weight and muscle cross-sectional area compared to the non-treated burn group, indicating a recovery of muscle mass.
The mechanism by which metformin mitigates burn-induced muscle wasting involves its ability to increase the number of muscle progenitors (Pax7+) and the protein level of Pax7, a transcription factor regulating the proliferation of muscle progenitors. Metformin treatment also significantly increases the proliferation of satellite cells, enhancing muscle regeneration and stem cell function. This rescuing of muscle atrophy is consistent with previous findings showing that metformin rescues muscle wasting in other injury models.
In summary, metformin's various metabolic effects and its modulation of stem cells make it a potential alternative to mitigate burn-induced muscle wasting while also managing hyperglycemia. However, further research is needed to fully understand the molecular mechanism of metformin in muscle and its potential applications in treating muscle atrophy post-burn injury.
Chemotherapy's Impact: Muscle Damage and Recovery
You may want to see also
Frequently asked questions
Yes, metformin has been shown to induce muscle atrophy by impairing muscle function through the regulation of myostatin in skeletal muscle cells.
Metformin regulates muscle growth inhibitor through the AMPK-FoxO3a-HDAC6 axis, which induces muscle atrophy.
The side effects of metformin include muscle atrophy, insulin resistance, and increased levels of p-AMPK and myostatin.
Metformin has been shown to have anti-senescent properties, which can help with muscle recovery and reduce fibrosis or excessive collagen. It is also an anti-diabetic agent that can manage hyperglycemia.
